Literature DB >> 15206042

[The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions].

S O Schmidt-Troschke1, T Ostermann, D Melcher, R Schuster, C M Erben, P F Matthiessen.   

Abstract

UNLABELLED: In Germany only few data is available on the use of stimulants in the treatment of Attention Deficit/Hyperactivity Disorder. For the first time a full survey of health insurance data was carried out on methylphenidate prescriptions from 2000 to 2001 in an East German District. 783 patients of the total cohort received at least one prescription for methylphenidate. In our sample, the treatment prevalence more than doubled in the observation period from 0.6 % to 1.4 % in children aged between 5 and 15 years, this age group representing the largest treatment group. Younger children, adolescents and adults were only rarely treated. The treatment was undertaken predominantly by paediatricians, general practitioners and neurologists/psychiatrists/child psychiatrists. Prescriptions were issued by one, or by not more than two doctors.
CONCLUSION: In Mecklenburg-Vorpommern the prevalence of stimulant treatment has clearly increased. Since diagnosis-related data is not available it is not possible to assess the indications for treatment. Further studies should serve to evaluate the correspondence between diagnosis and therapy in relation to stimulant medication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206042     DOI: 10.1055/s-2004-813322

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  9 in total

1.  Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013.

Authors:  Hélène Verdoux; Elodie Pambrun; Sébastien Cortaredona; Marie Tournier; Pierre Verger
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-01-07       Impact factor: 4.785

2.  Patterns and profiles of methylphenidate use both in children and adults.

Authors:  Vanessa Pauly; Elisabeth Frauger; Magalie Lepelley; Michel Mallaret; Quentin Boucherie; Joëlle Micallef
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

3.  Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Authors:  Edeltraut Garbe; Rafael T Mikolajczyk; Tobias Banaschewski; Ulrike Petermann; Franz Petermann; Angela A Kraut; Ingo Langner
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-12       Impact factor: 2.576

4.  The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.

Authors:  Ingrid Schubert; Ingrid Köster; Gerd Lehmkuhl
Journal:  Dtsch Arztebl Int       Date:  2010-09-10       Impact factor: 5.594

5.  Prevalence and patterns of methylphenidate use in French children and adolescents.

Authors:  Anne-Laure Knellwolf; Jean Deligne; Flavia Chiarotti; Guy-Robert Auleley; Serena Palmieri; Claudine Blum Boisgard; Pietro Panei; Elisabeth Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2007-11-20       Impact factor: 2.953

6.  Comorbidities in ADHD children treated with methylphenidate: a database study.

Authors:  Angela A Kraut; Ingo Langner; Christina Lindemann; Tobias Banaschewski; Ulrike Petermann; Franz Petermann; Rafael T Mikolajczyk; Edeltraut Garbe
Journal:  BMC Psychiatry       Date:  2013-01-07       Impact factor: 3.630

7.  Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data.

Authors:  Eric Acquaviva; Stéphane Legleye; Guy R Auleley; Jean Deligne; Didier Carel; Bruno Falissard B
Journal:  BMC Psychiatry       Date:  2009-11-17       Impact factor: 3.630

8.  Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS).

Authors:  Hildtraud Knopf; Heike Hölling; Michael Huss; Robert Schlack
Journal:  BMJ Open       Date:  2012-11-23       Impact factor: 2.692

9.  A three-country comparison of psychotropic medication prevalence in youth.

Authors:  Julie M Zito; Daniel J Safer; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Joerg M Fegert; James F Gardner; Gerd Glaeske; Satish C Valluri
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-25       Impact factor: 3.033

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.